Heather Williamson
Family · Munfordville, KYNPI 1437938842
Payments from drug & device makers
Across 133 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$484
- Bayer$392
- Corcept Therapeutics$318
- Novo Nordisk$168
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$151
- Lilly USA, LLC$121
- plus $492 from 14 others
What the payments were for
- Food & beverage$2,126100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $484 |
| Bayer | 26 | $392 |
| Corcept Therapeutics | 17 | $318 |
| Novo Nordisk | 9 | $168 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $151 |
| Lilly USA, LLC | 8 | $121 |
| AstraZeneca | 6 | $91 |
| Novartis | 3 | $56 |
| Abiomed | 2 | $49 |
| Lundbeck LLC | 2 | $47 |
| GSK | 3 | $45 |
| Amgen | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Dexcom, Inc. | 2 | $29 |
| Insulet Corporation | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Pfizer | 1 | $15 |
How this compares
$2,126 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $55,229 |
| EliquisApixaban | 30 | $25,075 |
| JardianceEmpagliflozin | 27 | $22,754 |
| MounjaroTirzepatide | 18 | $19,435 |
| LinzessLinaclotide | 23 | $17,050 |
| FarxigaDapagliflozin Propanediol | 15 | $14,228 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,482 |
| TradjentaLinagliptin | 20 | $7,590 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,563 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,013 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,903 |
| Levothyroxine Sodium | 145 | $1,245 |
| Metoprolol Succinate | 119 | $1,206 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $1,108 |
| Pantoprazole Sodium | 111 | $980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $168 | $55,22955 claims |
| PfizerEliquis | $15 | $25,07530 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $91 | $21,79027 claims |
| Lilly USA, LLCMounjaro | $121 | $19,43518 claims |
| AbbVieLinzess | $484 | $17,05023 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $45 | $15,38524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.
Other family in Munfordville
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.